Events Partner Content 4th Annual Gene Therapy for Rare Disorders Realize The Commercial Potential of Gene Therapies
Events Partner Content Gene Therapy for Blood Disorders Discover the Clinical & Commercial Potential of Gene Therapy & Editing Approaches Revolutionizing Hemophilia, Sickle Cell Disease & β-Thalassemia Treatment
Events Partner Content Gene Therapy Analytical Development In the context of unprecedented gene therapy clinical progress and mounting regulatory scrutiny, the inaugural Gene Therapy Analytical Development Summit will unite large pharma an
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
